Figure 2.
Decrease in renal function under agalsidase-beta dose reduction and switch to agalsidase-alfa. Change in renal function quantified by (A) eGFR (calculated with the CKD–Epidemiology Collaboration formula) and (B) albuminuria (albumin-to-creatinine ratio) from spot urine for the three visits. Appropriate values are given as medians (95% confidence intervals). Asterisks mark significant changes between baseline and prospective visits. P values are given in the figures.